NCT03888729View on ClinicalTrials.gov

Simplifying HCV Treatment in Rwanda for Elsewhere in the Developing World: Pangenotypic and Retreatment Study (SHARED3)

PHASE4UnknownINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

August 26, 2019

Primary Completion Date

March 31, 2020

Study Completion Date

March 31, 2020

Conditions
Hepatitis C, Chronic
Interventions
DRUG

sofosbubir/velpatasvir

SOF/VEL (400 mg/100 mg) FDC once daily

DRUG

sofosbubir/velpatasvir/voxilaprevir

SOF/VEL/VOX (400 mg/100 mg/100 mg) FDC once daily

Trial Locations (1)

Unknown

RECRUITING

Rwanda Military Hospital, Kigali

Sponsors

Lead Sponsor

Partners in Health
All Listed Sponsors
lead

Partners in Health

OTHER

NCT03888729 - Simplifying HCV Treatment in Rwanda for Elsewhere in the Developing World: Pangenotypic and Retreatment Study (SHARED3) | Biotech Hunter | Biotech Hunter